CARGO Therapeutics, Inc (CRGX) - Market Cap to Net Income Ratio

Corporate emblem and logo of CARGO Therapeutics Inc. (CRGX)

CARGO Therapeutics (CRGX) maintains a high scientific standing in developing advanced tumor-fighting methods, earning recognition from leading clinics. The business model relies on outsourcing all manufacturing processes and trials to third-party contractors, which minimizes capital expenditures. The current PE ratio is -1.00. The market price action for this developer of anticancer gene therapies is presented below.

CRGX cargo-tx.com: Price to Earnings Ratio in the range 08/14/2024 - 08/30/2025

Comprehensive metric breakdowns and analytics for CARGO Therapeutics Inc. (CRGX)

Comprehensive company analysis:CARGO Therapeutics Inc.
Signature product of CARGO Therapeutics, Inc.

Investors seek objective fundamental benchmarks in financial statements to assess asset value. The P/E ratio determines the relationship between market capitalization and annual net income, measuring the investment payback period. By analyzing the current P/E ratio, one can capture real-time changes in the market valuation of a business. For CARGO Therapeutics (CRGX), this indicator reflects the value of the organic development of its cell therapy pipeline. The independent expansion of its clinic network without M&A transactions makes this metric a key measure of internal investment efficiency.